Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Inhaled tobramycin versus intravenous tobramycin for patients with cystic fibrosis: a review of the clinical effectiveness, cost effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No evidence was identified comparing the clinical and cost effectiveness of inhaled tobramycin to IV tobramycin in the treatment of CF patients. A nephrotoxicity study of tobramycin on CF patients found that long-term use of neither inhaled nor IV tobramycin was associated with a decline in kidney function. Adherence rates with inhaled tobramycin were low. Despite no association found between inhaled tobramycin adherence and the frequency of pulmonary exacerbation, compared to patients with high adherence with inhaled tobramycin, those using less than 4 cycles of TIS per year were more likely to be hospitalized. Guidelines from the CF Foundation recommended that alternate month tobramycin solution for inhalation should be used chronically for infants who remain infected with PA after two attempts at eradication. Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Cystic Fibrosiss; Injections, Intravenous; Tobramycin Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000212 Date abstract record published 29/01/2014 |